Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: jobs report Friday

June 7, 2019 8:18am

Vertex (VRTX) acquires pre-clinical Duchenne muscular dystrophy gene editor, Exonics, giving a run for the money to Sarepta Therapeutics; Solid Biosciences (SLDB -$0.12) and Wave Life Sciences (WVE) watch out!

Pre-open indications: 3 BUYs, 2 SELLs and 3 TRADES

Unique insights from what's likely to remain a volatile climate; RMi outlines preludes and aftermaths defining the daily dose of factors, investment thesis and objectivity!

The 6 W’s: Who, what, where, when, why and what of it … the real question is who is going to do what?

Dow futures are UP +0.27% (+70 points), S&P futures are UP +0.28% (+8 points) and NASDAQ futures are also UP +0.37% (+27 points)

U.S. stock index futures were higher Friday looking for a fifth straight day of gains, amid hopes of progress on trade talks between the U.S. and Mexico;

European markets gain as investors digest ECB decision decided on Thursday, that it would … postpone its first interest rate hike, while raising its inflation forecast with the pan-European Stoxx 600 climbing 0.8% during the morning session;

Asia Pacific markets advanced following positive developments overnight on U.S.-Mexico negotiations, while investors digested recent comments from major central bank chiefs;

Data docket: May’s unemployment, nonfarm payroll and average hourly earnings figures are due to be released at 8.30 a.m. ET on Friday. Meanwhile, April’s wholesale trade data is due at 10 a.m. ET and consumer credit figures will be published at 3 p.m.

Economists polled by Reuters are forecasting that the U.S. will add 180,000 jobs during the course of May, yet if the figure is dramatically different to this, then this could impact the U.S. Fed’s current thinking surrounding interest rates.

Henry’omics:

Traders will be monitoring Friday’s ongoing talks, after stocks reached their high Thursday on reports that the U.S. was considering …delaying the imposition ….of a 5% tariff on Mexican imports, which is set to take effect on Monday.

From Thursday night’s post, “it ain’t easy to make a buck in this sector lately. Fundamentals let us down yet again, there is just no support even with news as any strength is to be sold into.”

I also stated, “It’s a highly fluid situation because we don’t know how any resolution on trade and tariffs will turn out but, the sector continues to be oversold and a comeback is in store as the “machines” tabulate the potential of an upside!”

The close was negative with an A/DL of 5/37 and 1 flat and 2 acquired;
Thursday’s range of the 6 upside was +0.38% (BOLD) to +7.17% (KOOL, post reverse) while the 37 downside ranged from -0.05% (ADVM) to -3.85% (RENE.L);
2 out of the 5 upside had higher than the 3 month average volume;
6 out of the 37 downside had higher than the 3 month average volume;
The iShares NASDAQ Biotechnology (IBB) indicator: closed down -0.17% after Wednesday’s +0.17% after Tuesday’s +1.93% after Monday’s+1.08% following the previous Friday closed down -1.78%;

Q2/19 so far:

In June, there were 2 positive and 2 negative close, so far;
In May, there were 14 negative, 1 holiday and 8 positive closes;
In April, there has been 10 positive and 11 negative closes;

Companies in my headlights – It’s your decision; I provide an idea and context: post earnings release:

Alnylam Pharmaceuticals (ALNY) closed up +$0.25 to $70.80 after Wednesday’s +$1.75 to $70.55. Tuesday’s +$1.93 to $68.80 and news of the completion of a rolling submission of an NDA to the U.S. FDA for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP). Givosiran previously received Breakthrough Therapy Designation from the FDA and Orphan Drug Designation in the U.S. for AHP – BUY to SELL;

Applied Genetic Technologies (AGTC) closed down -$0.08 to $3.60 after Wednesday’s flat at $3.68, Tuesday’s -$0.20 to $3.68 following Monday’s $3.88 and last Friday’s $3.65 - oversold on no news with 2^nd half results due. A trading stock, BUY;

BioMarin Pharmaceuticals (BMRN) closed down another -$3.10 to $80.49 after Wednesday’s-$0.19 to $83.59 after Tuesday’s +$1.71 to $83.78, Monday’s -$0.17 to $82.07 and last Friday’s -$1.14 to $82.24. BMRN announced today that Vimizim® has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition. – Maintaining BUY;

bluebird bio (BLUE) closed down again -$2.76 to $122.01 after Wednesday’s -$4.67 to $124.77 after Tuesday’s +$7.02 to $129.44, Monday’s $122.42, Friday’s $119.92, Thursday’s $120.53 and last Wednesday’s $122.25 - profit, Maintaining BUY;

CRISPR Therapeutics (CRSP) closed down -$0.28 to $37.25 after Wednesday’s +$0.27 to $37.53, Tuesday’s +$1.27 to $37.26, Monday’s +$0.42 to $35.99 and last Friday’s -$1.02 to $35.57 as May 1^st opened at $38.82, Overbought, – TRADE;

Editas Medicine (EDIT) closed up +$0.10 to $20.58 after Wednesday’s -$0.35 to $20.48, Tuesday’s +$0.07 to $20.83, Monday’s +$0.21 to $20.76 and last Friday’s -$0.68 to $20.55 – TRADE;

Intellia Therapeutics (NTLA) closed down again -$0.40 to $14.25 after Wednesday’s-$0.03 to $14.66 after Tuesday’s +$0.44 to $14.69, Monday’s +$0.37 to $14.25 and last Friday’s -$0.62 to $13.88. Needs some upside - TRADE

uniQure NA (QURE) closed down -$2.20 to $72,00 following Wednesday’s +$3.46 to $74.20 after Tuesday’s +$6.10 to $70.74 after Monday’s +$5.33 or +8.99% to $64.64 and last Friday’s $59.31, , Maintaining SELL;

ReNeuron (RENE.L) closed down another -$10.50 after Wednesday’s -$22.00, Tuesday’s -$5.00 to $295.00, Monday’s -$5.00 to $300.00 and last Friday’s at $305.00. RENE.L has a time differential trading with a market downside of -$5.00 – SELL;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.